A series of three guest posts from the BC Centre on Substance Use (BCCSU) about the new provincial guidelines for all health care professionals in BC involved in treating patients with opioid use disorders.
For more information and program resources, please visit www.bccsu.ca.
Recently, a decision was made by the Ministry of Health to provide coverage for the commercially available Metadol-D product (DIN 2244290) as an alternative for patients in the community who cannot take or are not benefiting from Methadose. As of May 28, 2019, Metadol-D (10mg/mL) is eligible for regular benefit coverage through PharmaCare.
IMPORTANT UPDATE (JANUARY 3, 2019)
There is currently a limited supply of Metadol-D®. At this time only patients that have already been approved through the special authority request process are able to continue on this medication due to limited supply.
Learn about the Provincial Opioid Addiction Treatment Support Program (POATSP) and Online Addiction Medicine Diploma developed by the BC Centre on Substance Use (BCCSU).
The BC Centre on Substance Use (BCCSU), in collaboration with the BC Ministry of Health, has released a new Guideline for the Clinical Management of Opioid Use Disorder. Effective June 5, 2017, this guideline is the provincial reference tool for all health care professionals in BC involved in treating patients with opioid use disorders.
Earlier this year, the BCCSU and the Ministry of Health (MoH) released a new Guideline for the Clinical Management of Opioid Use Disorder. Starting on June 5, 2017, this guideline will become the provincial reference tool for all health care professionals in BC involved in treating patients with opioid use disorders, and the management of the Provincial Methadone Program will transition from the College of Physicians and Surgeons of British Columbia to the BCCSU.